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Abstract
Background: The COVID-19 pandemic that started in March 2020 caused by the SARS-CoV-2
virus introduced an incredible number of unknowns that ongoing research aims to investigate.
One such unknown is the relationship between diabetes and COVID-19. Existing literature has
identified diabetes as a risk factor for poor health outcomes in COVID-19 patients, however,
other information is limited and inconclusive.
Objective: There are two primary goals of this scoping review. First, to consolidate existing
literature about both associations between COVID-19 and diabetes, and the biological
mechanisms of how diabetes and COVID-19 may interact. This includes consolidating
information about diabetes as a risk factor for contracting COVID-19, diabetes as a risk factor
for poor health outcomes in those infected with COVID-19, diabetic management during social
distancing, long-term symptoms in diabetic patients previously infected with COVID-19, and the
potential for new-onset diabetes as a long-term impact of COVID-19 infection. The second goal
of the review is to identify current gaps in knowledge and research.
Methods: Literature was selected from PubMed using specific inclusion and exclusion criteria.
After the selection process, the remaining literature was summarized and information from all of
the literature reviewed was categorized based on the theme.
Results: The initial searches yielded 428 results, and after filtering based on the criteria, there
were 95 results remaining. After reviewing the abstracts for the 95 results, 13 articles were
ultimately selected to be included in the scoping review based on relevancy to diabetes and
COVID-19.
Conclusion: There is insufficient research to draw any definitive conclusions about whether
diabetes is a risk factor for contracting COVID-19. Diabetes is a risk factor for poor health
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outcomes including hospitalization and mortality for those infected with COVID-19. Poorer
diabetes management during social distancing may have reduced glycemic control among
diabetic patients. There is a potential risk of developing new-onset Type 1 diabetes after
COVID-19 infection. Existing literature has primarily focused on diabetes as a risk factor for
poor health outcomes in patients with COVID-19 and the biological mechanisms of how diabetes
and SARS-CoV-2 interact. Further research should be conducted to learn more about diabetes as
a risk factor for contracting COVID-19, diabetes self-management during social distancing, and
long-term symptoms of patients with diabetes.
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Introduction
COVID-19 Overview
Since December 2019, the coronavirus disease (COVID-19) caused by SARS-CoV-2
virus has been a global health emergency. COVID-19 is a highly infectious respiratory disease
that was first discovered in late 2019 but has produced a multitude of virus variants. The high
basic reproductive value (R0) of 2-4 in addition to asymptomatic transmission has allowed
COVID-19 to cause a full global pandemic since March 2020 [4]. There have been over 6
million deaths directly caused by COVID-19 and almost 500 million confirmed cases worldwide
as of April 2022 [1]; however these figures, though significant, do not encompass all of the
damage that the pandemic has caused. Unreported COVID-19 cases and deaths, deaths
attributable to a lack of resources, and long-term COVID-19 symptoms are only a few of the
impacts unaccounted for. As further research is conducted about COVID-19, more information is
revealed about risk factors, impacts, etc.
The SARS-CoV-2 virus infects the body when the virus spike protein binds to the
angiotensin-converting enzyme 2 (ACE2) receptor, which is found in many cells including cells
in the nose, mouth, and lungs [31]. COVID-19 is a respiratory disease because the respiratory
system serves as an entryway for the virus to infect the rest of the body. ACE2 normally
functions to regulate blood pressure by breaking down angiotensin II, which is a hormone that
raises blood pressure via vasoconstriction [31]. This review will refer to the disease caused by
the SARS-CoV-2 virus including symptoms and long-term impacts as COVID-19, and will refer
to the actual virus that mechanistically interacts with cells as SARS-CoV-2.
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Diabetes Overview
Diabetes mellitus is a chronic disease that impacts the ability of a body to produce
insulin, which in turn impacts blood sugar levels. Insulin is a hormone produced by beta cells in
the pancreas that allows glucose from the blood to transport into the cell to be used for energy. In
patients with diabetes, insulin production is significantly reduced which means that glucose
cannot be used by cells and remains in the bloodstream. Furthermore, having hyperglycemia, or
high blood sugar, as a result of reduced insulin for long periods of time can cause a number of
comorbidities including heart disease, stroke, and kidney disease [29]. If not treated or regulated,
hyperglycemia can cause diabetic ketoacidosis, in which the body starts to break down fat for
energy when sufficient insulin is not available to transport glucose into cells [34]. A byproduct
of fat is ketones that can build up in the bloodstream and reduce the overall pH of the blood.
Diabetic ketoacidosis can be life-threatening [34].
In 2015, 9.4% of the United States population had diabetes, and over one-quarter of them
were unaware that they had diabetes [29]. Patients with diabetes often have comorbidities,
including hypertension which is treated by ACE inhibitor drugs that prevent angiotensin I from
converting to angiotensin II [31]. There are two main forms of diabetes: Type 1 and Type 2.
Patients with Type 1 diabetes cannot produce insulin on their own because their immune systems
attack their beta cells. These patients are generally diagnosed at a younger age. Patients with
Type 2 diabetes have a reduced ability to produce insulin often due to poor nutrition, low activity
levels, and age. These patients are generally diagnosed at an older age, and this form of diabetes
is the most common with approximately 92% of adults with diabetes having Type 2 diabetes
[29]. There are other forms of diabetes such as gestational diabetes, however, this review will
focus primarily on Type 1 and Type 2 diabetes.
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Viral Infections and Diabetes
There is existing research on how viral infections such as rotavirus, rubella virus, mumps
virus, coxsackievirus B, and cytomegalovirus may put people at a higher risk of developing
diabetes. Mechanistically, viral infections induce an immune response that results in antigen
presentation, which activates the release of inflammatory cytokines. The role of these cytokines
is to recruit, stimulate, and proliferate immune cells to combat viral infection [30]. Specifically,
the autoreactive effector T-cell in the immune system, in pursuit of fighting the viral infection,
can damage or destroy beta cells that produce insulin. This increases the risk of developing
diabetes, especially in those who are already predisposed to diabetes. Repeated viral infection
further increases this risk [15]. Similarly, increased viral load will yield a greater cytokine
response, which may progress into a cytokine storm. A cytokine storm can be life-threatening
because the immune system will aggressively attack the body’s tissues and organs-even to a fatal
point [32]. This kind of immune response is dangerous under any condition, but particularly for
patients with diabetes who may sustain too much damage to the pancreas which would further
reduce insulin production [32].

Existing Literature
The current literature available can be classified into two main categories:
1. Reported potential associations between diabetes and COVID-19 (ex. “Patients with
diabetes are at higher risk of poor health outcomes.”)
2. Proposed biological and technical mechanisms of how COVID-19 and diabetes interact
(ex. “The SARS-CoV-2 virus binds to the ACE2 receptor.”)
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Since 2020, research has become progressively more specific as more information about
COVID-19 has been discovered. The most recent general scoping review about COVID-19 and
diabetes found was in 2020. Other literature has been more specific to certain aspects of
COVID-19, which is helpful but not as generalizable. There are minimal recent observational
studies or experimental studies since those forms of research require longer periods of time. This
scoping review, thus, will fill a missing gap in current knowledge about COVID-19 and diabetes
as an overview.

Scoping Review Questions
The primary question guiding this review is:
What literature and knowledge is currently available on the interactions between diabetes and
COVID-19, and where are there gaps in the literature?

Secondary questions guiding this review are:
1. How is diabetes a risk factor for contracting COVID-19?
2. How is diabetes a risk factor for poor health outcomes in those infected with COVID-19?
3. How did self-management of diabetes during social distancing change?
4. What are the long-term symptoms in patients with diabetes previously infected with
COVID-19?
5. How might COVID-19 infection increase the risk of new-onset diabetes?
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Review Objective and Rationale
There are two main objectives for this scoping review.
1. Consolidate existing research about COVID-19 and diabetes into one source.
2. Evaluate potential gaps in research to better recommend future research.

The high rates of both diabetes and COVID-19 present concern for how the two diseases
may interact with one another. As a newer area of research, literature about COVID-19 and
diabetes is being published at a fast pace to push out as much information as possible. However,
there may be certain areas of research that have been prioritized thus far, causing other areas of
research to be overlooked. This review aims to summarize the types of literature currently
available and potential gaps in knowledge. Furthermore, there is a wide range of information
about diabetes and COVID-19 currently available, meaning that it is difficult to understand the
topic without significant research. This review can serve as an overview of COVID-19 and
diabetes to map key concepts in current literature and be used as a precursor for a systematic
review.

Research Design
Rationale for Scoping Review
A scoping review is the most appropriate method to explore existing literature given the
minimal information currently available about the topic and the short period of time that
information has been available for. Additionally, one of the goals of this review is to consolidate
maximal existing knowledge about the interaction between diabetes and COVID-19 in many
different contexts, with the understanding that new literature on the topic will continue to be
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rapidly released for the foreseeable future. The second goal of this review is to identify gaps in
research overall based on themes identified in the selected literature. Thus, a wider perspective is
necessary. The JBI Manual for Evidence Synthesis was used to justify conducting a scoping
review and as a guide for the format of this review [33]. The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) 2020 checklist was also used as a guide,
specifically for reporting the results of the review.

Eligibility Criteria:
Inclusion criteria
There were several inclusion criteria: Only literature from January 1st, 2021 onward was
included. This date was arbitrarily chosen, however, meant to signify an appropriate amount of
time since the beginning of the COVID-19 pandemic in March 2020 for recent enough and still
relevant research. All populations, languages, and countries of publication were included due to
limited existing literature. The literature included was from peer-reviewed journals and was
available in full for free. The article type was limited to clinical studies, observational studies,
meta-analyses, and reviews, although existing available literature is primarily reviews. In
accordance with JBI and PRISMA criteria for scoping reviews, these eligibility criteria were
defined a priori. The criteria are also minimally restrictive to allow for greater scope.

Exclusion criteria:
Literature that was published before January 1st, 2021 was excluded. Clinical trials were
excluded from the selection because they are interventional, and the goal of this review is to
understand how COVID-19 and diabetes interact on an observational level rather than
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treatments. Literature not readily available in full for free was not included. Furthermore,
literature that did not primarily focus on diabetes and COVID-19 was excluded. For example, a
study discussing multiple comorbidities including diabetes in the context of COVID-19 was
excluded because diabetes during COVID-19 was not the primary subject. This exclusion
criterion was enforced during the manual selection process of reviewing abstracts done by the
thesis author. This allowed the review to be more specific to the review objectives and removed
irrelevant information.

Search Strategy
In accordance with the two main categories of existing literature identified in the review
introduction, two separate searches were conducted. The first search started with “COVID-19
AND diabetes mellitus” followed by the keywords found in Table 1 to address the more
theoretical associations discussed. The second search started with “SARS-CoV-2 AND
hyperglycemia” followed by the keywords found in Table 1 to address the more technical
mechanisms discussed.
Table 1 lists the keywords used in the search. However, in filtering the search results, the
keywords were also used during the manual abstract review to decide whether the papers
retrieved were relevant and specific enough to diabetes and COVID-19 to include. Searches were
conducted in PubMed (keywords are provided in Table 1) in April 2022.
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Diabetes

COVID-19

Treatment

Outcome

New-Onset Diabetes

Pandemic

Self-Management

Morbidity

Diabetes Mellitus

Viral Infection

Telemedicine

Mortality

Mechanism

Diagnosis

Diabetic Ketoacidosis SARS-CoV-2
Risk Factor

Post COVID-19 Syndrome

Type 1/Type 2

Long COVID

Insulin

COVID-19

Hyperglycemia
Comorbidity
Table 1. Primary keywords of interest in searching for literature and filtering the literature

Search 1:
“COVID-19 AND diabetes mellitus AND ( diabetic ketoacidosis OR new-onset diabetes OR
type 1 OR type 2 OR insulin OR hyperglycemia OR comorbidity) AND (pandemic OR infection
OR SARS-CoV-2 OR post COVID-19 syndrome OR long COVID) AND (self-management OR
telemedicine OR mechanism) AND (morbidity OR mortality OR diagnosis)”

Search 2:
“SARS-CoV-2 AND hyperglycemia AND (diabetic ketoacidosis OR new-onset diabetes OR type
1 OR type 2 OR insulin OR diabetes OR comorbidity) AND (pandemic OR viral infection OR
COVID-19 OR post COVID-19 syndrome OR long COVID) AND (self-management OR
telemedicine OR mechanism) AND (morbidity OR mortality OR diagnosis)”
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Selection Process
The selection process for this scoping review included five steps. From the initial search
results, the results were filtered based on the date published, article type, free full-text
availability, and duplicates from a previous search. The last step of the selection process was
reviewing the abstracts of the remaining search results and selecting only the relevant literature
that focused primarily on diabetes and COVID-19.

Results
The two searches on PubMed resulted in a collective total of 428 results. After filtering
the results by date to exclude literature before January 1st, 2021, there were a total of 261 results.
Further filtering of literature not available as a free full text yielded 227 total results, and filtering
by article type yielded 107 results. After filtering out duplicates, 95 search results remained.
Filtering by article type yielded the greatest exclusion by filtering the results from 227 to 107.
This was primarily because a large fraction of the searched literature was reporting case
numbers, which was excluded since those reports were time-specific and thus were outdated at
the time this review was conducted. A manual filtering process was then used to assess the
remaining searches. The abstracts of the 95 results were reviewed by the thesis author and
filtered accordingly based on the exclusion criteria quality assessment. The main reason that
literature was excluded in this step was because it was too specific or was not in line with the
review objectives. Adhering to the review objectives, selection prioritized generalizability to
analyze a comprehensive overview on the topic. In total, 13 papers were selected in accordance
with the eligibility criteria for this scoping review [Figure 1].
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Pubmed Searches
Search 1

Search 2

Initial Results

361

67

Filtering by Date

220

41

Limit Text Availability

190

37

Limit Article Type

89

18

Remove Duplicates

89

6

Manual Filter (Abstract
Review)

11

2

Table 2. The literature selection process yielded 13 total articles in the review.

Analysis
Overall, 13 papers were selected in total for the scoping review. All 13 papers were
literature reviews, and all 13 were published within the past 12 months. After summarizing the
main points of each paper (Table 4, Table 5), six different themes were identified as commonly
discussed in the selected literature. The summaries of the key themes in each paper are provided
in Table 3.
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Study

Diabetes is
a risk
factor for
contracting
COVID-19

Diabetes is
a risk
factor for
poor health
outcomes
after
contracting
COVID-19

Metwally
et al.

X

X

Diabetes
self-manag
ement
during
social
distancing

Long-term
symptoms
patients
with
diabetes
after
COVID-19
infection

New-onset
diabetes
after
COVID-19
infection

X

X

Biological
mechanism
linking
diabetes
and
SARS-CoV
-2

Total
Themes
Discussed

4

Shreshtha
et al

X

Michalakis
K, Ilias I

X

X

X

3

X

X

X

4

X

X

4

Sabri et al

X

Mahrooz et
al

X

Kazakou et
al

X

Mahmudpo
ur et al

X

Unnikrishn
an et al

X

Yonekawa
A,
Shimono N

X

Roy S,
Demmer R

X

Srivastava
et al

X

Sardu et al.

X

Singh et al

X

1

X

X

X

X
X

2
X

2

X

4

X

3

1
X

X

3

X

3

X

X

3

X

Ratio

2/13

13/13

2/13

4/13

7/13

9/13

Percentage

15.4%

100%

15.4%

30.8%

53.8%

69.2%

Table 3. Review of which themes were discussed in each of the 13 articles in the review
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Table 3 offers insight into areas of study that are currently being prioritized and what
research is lacking. All 13 papers discussed diabetes as a risk factor for poor health outcomes
after COVID-19 infection and came to similar conclusions. Of the selected literature, 53.8%
discussed new-onset diabetes after COVID-19 infection with mixed conclusions, and 69.2% of
the selected literature discussed the biological mechanism of interaction between diabetes and
COVID-19. Additionally, 30.8% discussed long-term symptoms of COVID-19 among diabetic
patients, each of which determined that there is not enough information to draw a conclusion at
this point, and 15.4% of the selected literature discussed diabetes as a risk factor for contracting
COVID-19.
The studies included in this review reviewed a multitude of article types. Out of the 13
selected articles, 12 included observational studies, 7 included reviews, 6 included
meta-analyses, and 2 included experimental studies. In contrast to this review, the articles
included literature from 2020 which allowed for a greater range of article type than this scoping
review.

Diabetes as a Risk Factor for Contracting COVID-19
Among the papers that discussed this theme, none came to any definitive conclusions.
Metwally et al. and Sabri et al. suggest that there is evidence to support that hyperglycemia may
increase risk of contracting COVID-19, however, both ultimately conclude that the mechanism
of this association is still unclear and further research should be conducted [12, 17.].
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Diabetes as a Risk Factor for Poor Health Outcomes after COVID-19 Infection
Every article selected in this review concluded that diabetes is a risk factor for a poor
prognosis after COVID-19 infection. These poor health outcomes include hospitalization,
long-term symptoms, and mortality [12]. A study in China, also corroborated by a study in
England, found that the mortality rate among patients with diabetes who had been infected with
COVID-19 was approximately triple that of patients who did not have diabetes [23]. Poor
glycemic control was identified as a key risk factor for poor health outcomes after COVID-19
infection in both diabetic and non-diabetic patients [14]. Hyperglycemia severity on the first day
a patient is hospitalized for COVID-19 was found to be a strong predictor of prognosis, however,
the specific blood glucose levels have not been defined yet [23].

Diabetes Self-Management During Social Distancing
As a result of strict social distancing in response to increased COVID-19 cases, patients
with diabetes did not have access to the regular care they previously relied on to manage their
diabetes [22]. Poor management of diabetes can increase the risk of COVID-19 poor health
outcomes, loss of limbs, and mortality [22]. Telemedicine allowed patients to regularly speak to
their providers, but patients could not get their health metrics regularly checked. If further care
was needed, it had to be classified as severe enough to warrant a visit to a hospital where
resources were extremely limited and the risk of contracting COVID-19 was greater [22].
The pandemic also caused significant changes to lifestyle. Access to adequate nutrition,
insulin, and medication was limited because venturing into public spaces increased the risk of
COVID-19, especially for patients with diabetes. Overall regular physical activity decreased and
stress levels increased, which worsened diabetes management [Unnikrishnan]. The compounded
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effect of lifestyle changes and lack of access to care quickly became a significant concern for
patients with diabetes.

Long-Term Impact of COVID-19 in Patients with Diabetes
Metwally et al, Mahrooz et al, Unnikrishnan et al, and Srivastava et al. briefly discussed
potential long-term symptoms of COVID-19 infection among diabetic patients, but none of them
came to a definitive conclusion. Mahrooz et al suggested that diabetes is a risk factor for “long
COVID” which includes tiredness, muscle pain, joint pain, and breathlessness. Furthermore, the
severity of COVID-19 symptoms may be correlated to risk of new-onset diabetes, and potentially
overall immunity [20]. For example, a patient who experienced diabetic ketoacidosis is at higher
risk of long-term COVID-19 symptoms and contracting new infections than a patient who
experienced mild hyperglycemia [20]. Singh et al. discussed how vaccine immunity may wane
quicker in patients with diabetes, which is why vaccinating as many people as possible is so
important [19].

New-Onset Diabetes After COVID-19
There has been evidence that new-onset type 1 diabetes is a potential long-term impact of
COVID-19 [20]. There is currently insufficient data to draw any conclusions, however, the use of
corticosteroids in treating COVID-19, hyperglycemia, and metabolic dysfunction during
COVID-19 infection may be associated with new-onset diabetes [17]. Mahrooz et al. and Sabri et
al. suggest that while there is evidence to support that COVID-19 infection increases the risk of
new-onset diabetes, the mechanisms of this association are still unknown and further research
should be conducted [18, 17]. Evidence that viral infections such as rubella may be associated
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with new-onset diabetes has been available and accepted for a decade, so there is a biological
precedent for new-onset diabetes after COVID-19 infection [12]. It is also plausible that
new-onset diabetes is primarily a long-term impact of COVID-19 among people who were
already predisposed to a diabetes diagnosis [20]. Yonekawa et al. suggests that COVID-19 may
cause glycemic dysregulation even in previously healthy patients, which may result in new-onset
diabetes [23] Further research is necessary, however, to make more definitive conclusions.

Diabetes and SARS-CoV-2 Interacting Mechanism
The actual mechanism of why diabetes increases the risk of mortality and other poor
health outcomes in patients with COVID-19 is still being studied; however, several potential
possibilities have been proposed. In patients with uncontrolled diabetes, hyperglycemia allows an
increased rate of SARS-CoV-2 replication. This viral proliferation both increases the severity of
COVID-19 and quickens the progression of symptoms [28]. Patients with diabetes who
experience hyperglycemia would be administered an increased dose of insulin, which is
associated with an increase in cytokines that causes inflammation [28]. This response has the
potential to cause a cytokine storm, in which the immune system begins attacking its own
tissues, which can be life-threatening.
Another potential outcome of COVID-19 infection is beta cell damage. Appropriate
beta-cell function is critical for patients with diabetes because these cells produce insulin. ACE2
receptors where SARS-CoV-2 binds to are expressed in beta cells [14]. Accordingly,
SARS-CoV-2 impacts beta-cell function, thus impacting glycemic control [20]. Furthermore,
patients with diabetes are often on ACE inhibitor medications to manage co-existing
hypertension, however, these medications increase ACE2 expression and thus allow

20

SARS-CoV-2 greater opportunity to bind, infect, and progress [28]. The reason why diabetic
patients infected with COVID-19 are at so much higher risk of poor outcomes is that diabetes
worsens COVID-19 and COVID-19 worsens diabetes.

Discussion
Given these thematic breakdowns, it is clear that more research is needed to determine if
and how diabetes is a risk factor for contracting COVID-19, how diabetes self-management
changed during social distancing, long-term symptoms of COVID-19 among diabetic patients,
and new-onset diabetes. Even though 61.5% of the literature discussed new-onset diabetes, the
results were inconclusive suggesting that this is an area of research that should be prioritized. By
contrast, research about diabetes as a risk factor for poor health outcomes after COVID-19
infection may not need to be prioritized anymore because there is comparatively sufficient and
consistent literature that has determined that diabetes is a risk factor.
There are also clear gaps in the types of research being conducted. More recent literature
after January 1st, 2021 are primarily reviews. However, based on the articles reviewed in the
selected literature, there are very few experimental studies. Furthermore, though 12 of the 13
selected articles included observational studies, these studies were from before 2021. More
observational and experimental studies should be conducted moving forward to fill this gap, and
provide more recent data.
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Conclusion
Limitations
There were several clear limitations to this literature review. First, only reviews were
included. This was because most observational studies in the initial search were excluded since
they were from 2020. Other more recent observational studies were very specific, which was not
in line with the review objective of generalizability. Additionally, observational studies require
longer periods of time, meaning that the short timeframe has limited most literature about
COVID to reviews.
There is also a limitation on the information consolidated in this review itself due to the
timeline of COVID-19. Studies about COVID-19, and furthermore studies about diabetes and
COVID-19, are very recent, and more research is needed to draw more definitive conclusions.
Especially when evaluating long-term impacts, long periods of time are necessary for follow up.
Because of this, minimal clinical data is available, limiting the application of this scoping review.
Research is quickly being published, though, and more definitive conclusions can be made once
more information is available.

Overall Conclusion and Recommendations
This scoping review has effectively consolidated the existing literature regarding diabetes
and COVID-19 and has illuminated where further research is necessary. There is no definitive
conclusion if diabetes is a risk factor for contracting COVID-19, how diabetes self-management
was impacted during social distancing, long-term symptoms after COVID-19 infection in
patients with diabetes, and new-onset diabetes after COVID-19 infection. Accordingly, these are
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areas of research that should be prioritized moving forward. Every article selected did conclude
that diabetes is a risk factor for poor health outcomes after contracting COVID-19 and there is
sufficient evidence to support the proposed biological mechanisms between diabetes and
COVID-19. There were no notable discrepancies in conclusions between the selected literature.
Although there were varying degrees of confidence in certain conclusions, all authors agreed that
at this point no definitive conclusions can be made due to limited information. All of the papers
emphasized the importance of further research. Developing novel strains of COVID-19 continue
to pose a threat in the pandemic, and research should continue because it is valuable to have the
appropriate information in order to develop treatments. As more time passes, greater research
will be available about the interaction between COVID-19 and diabetes.
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Appendix
Search 1:
“COVID-19 AND diabetes mellitus AND ( diabetic ketoacidosis OR new-onset diabetes OR
type 1 OR type 2 OR insulin OR hyperglycemia OR comorbidity) AND (pandemic OR infection
OR SARS-CoV-2 OR post COVID-19 syndrome OR long COVID) AND (self-management OR
telemedicine OR mechanism) AND (morbidity OR mortality OR diagnosis)”

Study

Date
Published

Studies
Included

Summary Findings

Metwally et
al.

December
2021

Observational,
review

● Preexisting diabetes shows higher
COVID-19 incidence and outcomes
● Higher frequency of diabetes onset and
complications after COVID-19 infection
● New onset diabetes may be a novel form
● New technologies may be used to combat
this bidirectional relationship
● There is a history of Type 1 diabetes
induced by viral infection

Shreshtha et al September
2021

Observational

● There is a bidirectional relationship
between diabetes and COVID-19
● Meta-analysis of observational studies
● Increased mortality in hyperglycemic,
previously diabetic, and newly diabetic
patients compared to those without
diabetes
● Higher rate of new-onset diabetes and
hyperglycemia

Michalakis K,
Ilias I

May 2021

Observational,
review

● Hyperglycemia can worsen symptoms
regardless of diabetes diagnosis
● COVID-19 causes inflammation in beta
cells, which may increase risk of diabetes

Sabri et al

October
2021

Observational,
review,
meta-analysis

● Lack of beta cells or insulin resistance
may be a risk factor for developing
COVID-19
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● Diabetic patients often have other
comorbidities that put them at higher risk
of COVID-19 infection and mortality
● Corticosteroid used to treat COVID-19 is
associated with new onset diabetes
● Insulin resistance may be due to the
alternate pathway of SARS-CoV-2 of the
RAS
Mahrooz et al

May 2021

Observational,
meta-analysis,
review

● COVID-19 impacts cellular metabolism,
thus decreasing ATP generation
● SARS-CoV-2 can cause a cytokine storm
● Metabolic dysfunction impacts COVID-19
treatment
● Long-term symptoms for diabetic patients
recovered from COVID-19 are unknown
● COVID-19 may increase risk of new-onset
diabetes via metabolic dysfunction

Kazakou et al

February
2022

Observational,
experimental,
meta-analysis

● Greater risk of poor health outcomes in
diabetic patients diagnosed with
COVID-19
● COVID-19 may cause metabolic
dysregulation and impaired glucose
homeostasis
● New-onset diabetes after COVID-19
provides evidence of the role of
COVID-19 in glucose metabolism

Mahmudpour
et al

January
2022

Experimental,
observational

● Insulin resistance due to SARS-CoV-2
may cause metabolic deterioration in
diabetic patients
● There are multiple metabolic pathways
that COVID-19 may be disturbing
● The diabetes molecular tetrahedron
provides a visual representation of the
diabetes and COVID-19 relationship, thus
yielding more insight into potential
therapies

Unnikrishnan
R, Misra A

September
2021

Observational,
review

● Diabetes is a risk factor for poor health
outcomes in COVID-19 patients
● Poor glycemic control caused by
COVID-19 may be due to pancreatic
damage, use of corticosteroids, and
cytokine storm
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● Diabetic patients had limited access to
care, adequate nutrition, and exercise due
to social distancing
Yonekawa A,
Shimono N

March
2022

Observational,
experimental,
meta-analysis,
review

● Glycemic state prior to COVID-19
infection may impact risk of new-onset
diabetes
● The exact mechanism of why diabetes is a
risk factor in COVID-19 patients
continues to be investigated
● COVID-19 variants may behave
differently in terms of impacting glycemic
control

Roy S,
Demmer R

March
2022

Observational

● The strength of evidence in COVID-19
and diabetes studies is unknown
● The studies reviewed did not adequately
adjust for confounders
● Treating hyperglycemia may not impact
COVID-19 outcomes
● Measuring key diabetes biomarkers in
non-diabetic patients infected with
COVID-19 may be key to treatment

Srivastava et
al

March
2022

Observational

● The actual mechanism of why diabetes is a
risk factor for COVID-19 patients
● Cytokine storm leads to decreased
function of T helper cells
● SARS-CoV-2 binds to ACE-2, which
activates the RAS pathway, yielding more
inflammation and causing greater insulin
resistance
● Inflammatory response could make
existing heart conditions worse

Table 4. Summaries of selected literature from search 1.
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Search 2:
“SARS-CoV-2 AND hyperglycemia AND (diabetic ketoacidosis OR new-onset diabetes OR type
1 OR type 2 OR insulin OR diabetes OR comorbidity) AND (pandemic OR viral infection OR
COVID-19 OR post COVID-19 syndrome OR long COVID) AND (self-management OR
telemedicine OR mechanism) AND (morbidity OR mortality OR diagnosis)”
Date
Published

Studies
Included

Summary Findings

Sardu et al.

March
2022

Experimental,
meta-analyses,
review

● Hyperglycemia is a risk factor for poor
health outcomes in COVID-19 patients
regardless of diabetes diagnosis
● Managing hyperglycemia critical for
improving clinical outcomes

Singh et al

March
2022

Meta-analysis,
observational

● Diabetes is a risk factor for poor outcomes
in COVID-19 patients
● Focusing on anti-inflammatory treatment
for COVID-19 may reduce poor health
outcomes due to diabetes and reduce the
potential for new-onset diabetes

Table 5. Summaries of selected literature from search 2.
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Figure 1. Study selection flow chart [PRISMA]
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